Home Cart Sign in  
Chemical Structure| 39524-08-8 Chemical Structure| 39524-08-8

Structure of Asperosaponin VI
CAS No.: 39524-08-8

Chemical Structure| 39524-08-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Asperosaponin VI, a natural product isolated and purified from the root of Dipsacus asperoides, may exert apoptosis-inducing activity via induction of apoptosis through activation chiefly via the nitric oxide and apoptosis-related p53 and Bax gene expression.

Synonyms: Akebia saponin D; ASA VI; Tauroside St-G0-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Asperosaponin VI

CAS No. :39524-08-8
Formula : C47H76O18
M.W : 929.10
SMILES Code : O=C(O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)[C@]34CCC(C)(C[C@@]3([H])C5=CC[C@@]6([C@@]7([C@]([H])([C@](CO)([C@@H](O[C@@H]8OC[C@@H]([C@@H]([C@H]8O)O)O)CC7)C)CC[C@@]6(C)[C@]5(C)CC4)C)[H])C
Synonyms :
Akebia saponin D; ASA VI; Tauroside St-G0-1
MDL No. :MFCD25371916

Safety of Asperosaponin VI

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Asperosaponin VI

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary microglia 40 μM 24 h To investigate the effect of Asperosaponin VI on microglial phenotype, results showed that it induced a switch from pro-inflammatory (iNOS+) to neuroprotective (Arg-1+) phenotype via PPAR-γ pathway J Neuroinflammation. 2022 May 24;19(1):115
Rat primary chondrocytes 100 μM 24 h Evaluate the effect of AVI on IL-1β-induced OA chondrocytes, results showed AVI reversed the decrease in cell viability caused by IL-1β, inhibited MMP13 expression and increased Collagen II expression Front Pharmacol. 2025 Feb 28;16:1539092
human umbilical vein endothelial cells (HUVECs) 20–80 μg/mL 48 h ASA VI dose-dependently promoted the proliferation, migration, and enhanced angiogenic ability of HUVECs in vitro, associated with up-regulated HIF-1α/VEGF signaling. Acta Pharmacol Sin. 2018 Mar;39(3):393-404
Caco-2 cells 500 μg/mL 1 hour Evaluate the uptake of ASP VI and ASP VI-NaTC-DOPC-SAN in Caco-2 cells. Results showed that the cellular uptake rate of ASP VI-NaTC-DOPC-SAN was significantly increased by 13.18-fold compared to ASP VI. Int J Nanomedicine. 2023 Dec 6;18:7335-7358

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Chronic mild stress (CMS)-induced depressive-like behavior model Intraperitoneal injection 40 mg/kg Once daily for 3 weeks To investigate the effect of Asperosaponin VI on CMS-induced depressive-like behaviors, results showed that it ameliorated depressive-like behaviors via PPAR-γ pathway and induced a switch of hippocampal microglia from pro-inflammatory (iNOS+-Iba1+) to neuroprotective (Arg-1+-Iba1+) phenotype J Neuroinflammation. 2022 May 24;19(1):115
SD rats Full-thickness cutaneous wound model Intravenous injection 20 mg/kg Once daily for 21 days ASA VI significantly promoted cutaneous wound healing, with more blood vessels observed in regenerated tissue. Rapid vascularization accelerated cellular proliferation, granulation tissue formation, collagen matrix deposition, and remodeling, leading to efficient wound healing. Acta Pharmacol Sin. 2018 Mar;39(3):393-404
Sprague Dawley (SD) rats Single-pass intestinal perfusion model Oral 150 mg/kg Single dose Evaluate the absorption and bioavailability of ASP VI-NaTC-DOPC-SAN in vivo. Results showed that the relative bioavailability of ASP VI-NaTC-DOPC-SAN was 326.3%, significantly higher than that of ASP VI. Int J Nanomedicine. 2023 Dec 6;18:7335-7358

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.08mL

0.22mL

0.11mL

5.38mL

1.08mL

0.54mL

10.76mL

2.15mL

1.08mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories